ION337 Enters Dravet Race Last: Preclinical Promise Meets Clinical Void and Entrenched Competition

Ionis Doses First Participant in ASCEND Trial for Dravet Syndrome

Ionis Pharmaceuticals has dosed the first participant in its Phase I-II ASCEND trial, evaluating ION337, an investigational RNA-targeted therapy, for children aged two to 12 years with Dravet syndrome. This open-label study aims to advance a potential disease-modifying therapy for this rare and severe neurological disorder, which is characterized by prolonged seizures and developmental delays. ION337, developed using Ionis’ NMA technology, is designed to increase the production of the NaV1.1 protein, often reduced in Dravet syndrome patients. The US FDA has granted Fast Track designation to ION337 for this indication.

• The ASCEND trial is an open-label, Phase I-II study enrolling children aged two to 12 years who have a clinical diagnosis of Dravet syndrome. The trial design includes a six-month single-ascending dose segment, followed by a 24-month multiple-ascending dose phase where ION337 is administered every six months, and concludes with a seven-month safety follow-up.
• ION337 is an RNA-targeted therapy developed using Ionis’ N-Methylacetamide (NMA) technology. This technology is designed to improve the potency of splice-modulating antisense oligonucleotides, aiming to support sustained activity with less frequent intrathecal dosing. The drug specifically targets and is designed to increase the production of the NaV1.1 protein, which is often reduced in patients with Dravet syndrome due to SCN1A gene variants.
• The US Food and Drug Administration (FDA) has granted Fast Track designation to ION337 for Dravet syndrome, highlighting the urgent need for new therapeutic options for this severe neurological condition. This milestone marks Ionis’ first wholly-owned medicine developed with its advanced NMA technology, signifying a new wave of scientific innovation within the company’s neurology pipeline.

Addressing Unmet Needs in Dravet Syndrome Treatment

Dravet syndrome (DS) presents a constellation of treatment challenges that span pharmacological resistance, knowledge gaps in long-term outcomes, and incompletely characterized disease mechanisms. These limitations collectively constrain the ability of clinicians to deliver optimized, personalized care across the full patient lifespan.

• Inherent drug resistance: Refractoriness to antiseizure medications is a defining feature of DS. Even with combination therapy including agents such as valproate, a substantial proportion of patients fail to achieve adequate seizure control, underscoring the refractory nature of the condition.

• Paucity of adult-focused research: The long-term natural history of DS into adulthood remains poorly characterized, reflected in a striking 7:1 ratio of pediatric-only to adult-only studies (208 vs. 28 exclusive studies, with 116 involving both populations). Further research in older adult cohorts is necessary to understand disease trajectory and inform long-term management strategies.

• Persistent morbidity and mortality in adulthood: Adult patients continue to experience significant behavioral problems associated with reduced health-related quality of life, and Sudden Unexpected Death in Epilepsy (SUDEP) represents the leading reported cause of death in adults with DS.

• Unresolved neuroinflammatory mechanisms: Systemic and neuroinflammatory changes in DS are associated with increased STAT3 signaling. Baseline inflammatory indices — including neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and CRP — are significantly elevated in drug-resistant epilepsy compared to self-limited epilepsy (p < 0.001). CRP has been identified as an independent predictor of progression to drug resistance (OR = 2.79, p = 0.025); however, the precise molecular link between systemic inflammation and CNS signaling remains unclear.

• Gaps in genotype-phenotype understanding: Comprehensive genetic testing beyond SCN1A is needed to support personalized therapeutic decision-making. More severe genetic mutations correlate with more severe clinical manifestations, highlighting the critical importance of advancing genotype-phenotype correlation frameworks for tailored intervention.

Unpacking the Genetic Roots of Dravet Syndrome

Dravet syndrome is driven predominantly by mutations in SCN1A, the gene encoding the alpha-1 subunit of the voltage-gated sodium channel Nav1.1, which account for 70–90% of cases. The vast majority of these mutations arise de novo, with approximately 75% originating from the paternal chromosome — a bias attributable to the greater number of mitotic divisions during spermatogenesis and the heightened susceptibility of methylated sperm DNA to mutagenesis. Pathogenic SCN1A variants span a broad mutational spectrum, including point mutations, microdeletions, whole-gene deletions, and copy number variants, with over 700 distinct mutations documented. Loss-of-function is the predominant molecular consequence, though gain-of-function mechanisms have also been described. Notably, deep intronic variants associated with poison exons — particularly in introns 1, 20 (20N), and 22 — represent a mechanistically distinct class, where aberrant exon inclusion during pre-mRNA splicing leads to non-functional transcripts; this finding has direct therapeutic relevance, as splice-modulating antisense oligonucleotides (ASOs) targeting poison exon 20N have emerged as a potential disease-modifying strategy.

Beyond SCN1A, a constellation of additional genes contributes to the Dravet syndrome phenotype. PCDH19 variants account for approximately 16% of cases, particularly in SCN1A-negative females. Variants in SCN1B (encoding the sodium channel β1 subunit), SCN2A, GABRG2 (γ2 subunit of GABA-A receptors), GABRB2, GABRA1, STXBP1, HCN1, CHD2, and CSNK2B have all been identified in Dravet syndrome patients. GABA receptor subunit mutations — particularly in GABRA1 and GABRB2 — exert their pathogenic effects primarily through defects in receptor gating, while GABRG2 variants more commonly impair receptor trafficking. CSNK2B mutations disrupt casein kinase 2 activity, with downstream consequences for synaptic plasticity that converge mechanistically with dysfunction observed in other Dravet-associated genes.

Phenotypic severity in Dravet syndrome is not determined solely by variant type or location but is substantially shaped by genetic modifiers. Evidence from Scn1a mouse models illustrates this clearly: mice on the 129S6/SvEvTac background exhibit no overt phenotype, whereas F1 hybrid mice (C57BL/6J × 129) develop severe epilepsy with high rates of premature death. Several Dravet syndrome modifier (Dsm) loci have been identified, including Dsm5, localized to a 5.9 Mb region on chromosome 11, with candidate modifiers encompassing brain-expressed protein-coding genes and two miRNAs predicted to regulate Scn1a transcript levels. Similarly, CACNA1A variants appear to act as phenotypic modifiers in SCN1A mutation carriers, with co-occurrence associated with earlier seizure onset, more frequent prolonged seizures, and a higher prevalence of absence seizures — consistent with gain-of-function biophysical changes observed in novel Cav2.1 variants identified in this context.

Designing the ASCEND Trial for ION337 in Dravet Syndrome

Clinical trials in Dravet syndrome span a range of therapeutic modalities — from small-molecule adjunctive therapies to gene-modifying antisense oligonucleotides — each employing distinct design parameters and endpoint frameworks. The table below consolidates key design and endpoint data across the most clinically and strategically relevant trials, providing a structured reference for benchmark-setting in the ION337 ASCEND program.

Precision Targeting Dravet: ION337's Clinical Journey Begins

The initiation of the ASCEND trial for ION337 represents a pivotal moment in the fight against Dravet syndrome, a devastating pediatric epilepsy largely driven by SCN1A haploinsufficiency and characterized by intractable seizures, developmental delays, and a high risk of sudden unexpected death in epilepsy (SUDEP). Unlike existing symptomatic treatments, ION337 is designed to directly address the underlying genetic defect by increasing NaV1.1 protein production, offering the promise of a truly disease-modifying therapy. This approach aligns with the broader shift towards precision medicine in rare neurological disorders, where RNA-targeted therapies, particularly antisense oligonucleotides (ASOs), have shown significant promise in conditions like spinal muscular atrophy and Huntington's disease.

However, the path forward is not without its complexities. While the Fast Track designation acknowledges the urgent unmet need and may accelerate development, several factors warrant careful consideration. The requirement for intrathecal administration, a common delivery method for CNS-targeted ASOs, can lead to adverse events such as post-lumbar puncture syndrome and elevated CSF protein, which must be carefully managed, especially in a young, vulnerable patient population. Furthermore, translating preclinical success in mouse models to consistent clinical benefit in humans, given the broad phenotypic spectrum of Dravet syndrome, remains a significant hurdle. The therapeutic landscape for Dravet syndrome is also rapidly evolving, with other ASOs and gene therapies in development. ION337 will need to demonstrate a robust and differentiated profile in terms of efficacy, safety, and long-term impact on both seizure control and critical comorbidities to establish its place in future treatment paradigms. Ultimately, the success of ION337, and similar precision therapies, will hinge on not only reducing seizures but also meaningfully improving the overall quality of life and developmental trajectories for children living with this challenging condition.